Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor (TKI). The oral drug candidate, which Korea’s Yuhan is licensing from its compatriot J INTS BIO, is designed for use in non-small cell lung cancer […]

Yuhan Corporation acquires Progen, a multi-target antibody company based in South Korea for total of $23M investment

Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target antibody-based platform technology.  Progen Inc. is a biotechnology company with 25 years of experience in platform-based drug discovery and development. The company has a platform technology for immunoglobulin […]